ORIGINAL ARTICLE. Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma
|
|
- Eugene Morgan
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma Cecelia E. Schmalbach, MD; Brian Nussenbaum, MD; Riley S. Rees, MD; Jennifer Schwartz, MD; Timothy M. Johnson, MD; Carol R. Bradford, MD Objectives: To determine (1) the reliability of sentinel lymph node mapping with biopsy (SLNB) in head and neck cutaneous melanoma to accurately stage nodal basins and (2) the safety of SLNB in both the neck and parotid regions. Design: Retrospective cohort study with a median follow-up of 25 months. All patients had a minimum follow-up of 1 year. Setting: Academic medical center. Patients: Eighty evaluable patients diagnosed as having head and neck cutaneous melanoma and staged using SLNB. Interventions: Sentinel lymph nodes were identified using preoperative lymphoscintigraphy and a combination of intraoperative gamma probe and isosulfan blue dye. Patients with a SLN positive for melanoma underwent therapeutic lymphadenectomy followed by an evaluation for adjuvant therapies. Patients with a negative SLNB result were followed up clinically. Main Outcome Measures: Percentage of positive SLNs, regional recurrence in the setting of a negative SLNB result (false-negative rate), and procedure complications. Results: The mean Breslow depth was 2.35 mm. A SLN was identified in 77 (96.3%) of cases, with an average of 2.18 nodes per patient. Of the sentinel nodes identified, 74% were from the neck region. The remaining 26% were from the parotid basin. No facial nerve complications occurred. Of the patients, 14 (18%) were SLN positive for metastatic melanoma. The regional failure rate in the setting of a negative SLNB result was 4.5%. Conclusions: Sentinel lymph node mapping with biopsy is a reliable technique to diagnose regional spread from head and neck cutaneous melanoma. This procedure can be performed in both neck and parotid nodal basins with safety and accuracy similar to non head and neck sites. Arch Otolaryngol Head Neck Surg. 2003;129:61-65 From the Department of Otolaryngology Head and Neck Surgery (Drs Schmalbach, Nussenbaum, Johnson, and Bradford), Department of Surgery, Section of Plastic Surgery (Dr Rees and Johnson), and Department of Dermatology (Drs Schwartz and Johnson), University of Michigan, Ann Arbor. NUMEROUS QUESTIONS surround the management of head and neck cutaneous melanoma, especially with respect to the role for elective treatment of regional nodal basins. Prospective randomized trials have failed to demonstrate a survival benefit for patients with melanoma undergoing elective lymphadenectomy. 1,2 While nodal status is clearly recognized as the most significant prognostic factor for patients diagnosed with cutaneous melanoma, only 10% to 20% of patients present with occult lymph node metastasis. This risk for nodal metastasis increases as primary tumor thickness increases. Lesions less than 1 mm thick are associated with a less than 5% rate of regional metastasis, while lesions thicker than 4 mm are associated with a 30% to 50% rate of nodal involvement. 3,4 In an attempt to identify this small group of patients harboring occult nodal disease using a minimally invasive procedure, Morton et al 5 introduced sentinel lymph node mapping with biopsy (SLNB) for the evaluation of patients with trunk and extremity cutaneous melanoma. They demonstrated that the status of the SLN accurately represented the status of the entire nodal basin from which it was obtained. In doing so, SLNB provided a means of identifying patients with occult nodal metastasis who warranted therapeutic lymphadenectomy and adjuvant therapy, while sparing the remaining 80% of patients without regional disease the morbidity associated with formal lymphadenectomy. Recent multivariate analysis involving patients with stage I and II melanoma by Gershenwald et al 6 found the pathological status (positive or negative for 61
2 Table 1. Distribution of Head and Neck Cutaneous Melanoma Location No. (%) of Cases Cheek 16 (20) Scalp 16 (20) Neck 13 (16) Auricle 13 (16) Forehead 5 (6) Temple 4 (5) Mentum 4 (5) Preauricular 4 (5) Cutaneous lip 2 (3) Nose 1 (1) Postauricular 1 (1) Eyelid 1 (1) metastasis) of the SLN to be the most important prognostic factor for recurrence and survival. While SLNB has a defined role in the evaluation of cutaneous melanoma of the trunk and extremities, several questions remain unanswered with respect to its application in the head and neck region. 7 The complexity of the head and neck lymphatic system has caused concern surrounding the reliability of SLNB to accurately reflect the status of the entire nodal basin. The popularity of SLNB in this region has also been limited by technical difficulties, 8 concern surrounding damage to vital structures such as the facial nerve, 8 and the necessity for nuclear medicine staff as well as pathologists who specialize in SLNB technique. The objective of this retrospective cohort study was to determine the reliability of SLNB for regional staging of head and neck cutaneous melanoma. METHODS Approval for this study was granted by the University of Michigan Medical School Institutional Review Board for Human Subject Research, Ann Arbor. This retrospective cohort study included 87 patients (7 of whom were lost to follow-up) treated for head and neck cutaneous melanoma who were staged using SLNB by the senior authors (C.R.B. and R.S.R.). Patients were identified through a query of the prospective University of Michigan Melanoma Database from April 1998 through December All patients who had histologically proven melanoma with a minimum Breslow depth of 1.00 mm (or 1.00 mm in the setting of other adverse prognostic variables such as ulceration, tumor extension to the deep margin, extensive regression, or young age) in the clinical absence of regional or distant metastasis were counseled for SLNB. Patients who underwent the procedure were included in the analysis. All patients were initially evaluated with a comprehensive consult by the University of Michigan Multidisciplinary Melanoma Clinic. Patients who underwent prior melanoma excision with wide margins or prior neck surgery were excluded due to the decreased accuracy in identifying the true SLN. Only patients with a minimum follow-up of 1 year were included in the analysis. All patients underwent preoperative lymphoscintigraphy to determine the number, location, and laterality of nodal basins at risk for metastatic disease. The lymphoscintigraphy was performed 2 to 4 hours prior to surgery using techniques previously described. 9 Specifically, a mean dose of 2.3 µci (range, µci) of technetium Tc 99m sulfur colloid (CIS-US Inc, Bedford, Mass) was injected intradermally into the 4 quadrants surrounding the primary melanoma lesion. Planar imaging was performed 15 to 30 minutes following injection (E.CAM; Siemens, Hoffman Estates, Ill). Intraoperative lymphatic mapping with isosulfan blue dye (1% Lymphazurin; Hirsch Industries Inc, Richmond, Va) was performed using previously described techniques. 5 Approximately 1 ml of dye was injected into the intradermal layer surrounding the primary melanoma lesion. Following wide local excision of the primary lesion, nodal basins were evaluated for increased radioactivity using a handheld gamma probe (Navigator GPS; RMD Instruments, Watertown, Mass). A 1- to 3-cm incision was made overlying the areas of increased radioactivity. A preauricular incision was used for SLNB in the parotid region. Sentinel lymph nodes were identified using a combination of gamma probe and blue dye. Each SLN was individually dissected from surrounding tissue. It was the preference of one of the 2 surgeons to use continuous facial nerve monitoring for SLNB within the parotid nodal basin (Viking; Nicolet Instrument Corporation, Madison, Wis). The staging procedure was considered complete when all nodal basins had minimal background radioactivity relative to the primary lesion and sentinel nodes. All SLNs were sent for histologic evaluation using permanent sections. Histologic evaluation included serial sectioning and staining with hematoxylin-eosin (H&E). Special immunohistochemical staining for S100, melan-a, and HMB-45 were performed for all SLNs that were negative on H&E staining. Patients with a SLN positive for metastatic melanoma underwent therapeutic lymphadenectomy within 2 weeks of the biopsy. Counseling for adjuvant interferon alfa-2 was performed in the setting of a positive lymph node. In addition, adjuvant radiation was recommended for patients when metastatic disease involved 3 or more lymph nodes or when extracapsular spread was identified. The remaining patients with a negative SLNB result were followed up clinically. The University of Michigan Melanoma Database was used to define the population demographics. Main outcome measures included the percentage of positive SLNs, regional recurrence in the setting of a negative SLNB result (false-negative rate), and facial nerve injury. RESULTS Eighty-seven patients treated between April 1998 and December 2000 met the inclusion criteria for this study. Seven patients were lost to follow-up. Of the remaining 80 evaluable patients, 54 (68%) were men and 26 (32%) were women. The median patient age was 55 years (range, 7-86 years). The mean Breslow depth was 2.35 mm (range, mm). Melanoma subtypes included superficial spreading (32%), unclassified (21%), nodular (20%), lentigo maligna (19%), desmoplastic (5%), spindle cell (1%), polypoid melanoma (1%), and neurotropic (1%). Fourteen percent of the lesions were ulcerated. The distribution of the primary melanoma lesions are listed in Table 1. Using the combined techniques of lymphoscintigraphy, intraoperative gamma probe, and isosulfan blue dye, a SLN was found in 77 (96%) of the 80 cases performed. The average number of SLNs identified per patient was 2.18 (range, 1-7 nodes). Of the 168 SLNs, 74% were identified in neck nodal basins. The remaining 26% were found within the parotid bed. Of the 30 patients with SLNs that drained to the parotid basin, 28 (93%) underwent successful SLNB. One patient underwent success- 62
3 Table 2. Distribution of Sentinel Lymph Node Biopsy (SLNB) Results According to Breslow Depth* Patients Total, No Positive SLNB result, No. (%) 2 (20) 4 (12) 5 (22) 3 (25) *One patient did not have Breslow depth reported. ful SLNB in a neck nodal basin but required a superficial parotidectomy because of the deep location of a second SLN within the superficial lobe. This parotid SLN was identified in the surgically removed lobe using the gamma probe. The hot node was sent separately for histologic review and was found to be negative for metastatic disease. A second patient experienced significant intraoperative bleeding from the parotid tissue. The procedure was aborted due to the associated risk to the facial nerve, and the patient was followed up clinically. This patient remains free of disease at a follow-up interval of 36 months. There was minimal morbidity related to this procedure. No anaphylactic reactions occurred following injection of isosulfan blue dye. There were no cases of cranial nerve damage, and all patients had normal postoperative cranial nerve function, including the facial nerve. No damage to vital neck structures was reported. Of the patients, 14 (17.5%) had metastatic melanoma identified using SLNB. A breakdown of SLNB results according to Breslow depth is provided in Table 2. All of these patients subsequently underwent therapeutic lymphadenectomy. Specifically, the neck nodal basins were treated with a modified radical neck dissection sparing the sternocleidomastoid muscle, internal jugular vein, and spinal accessory nerve. A posterolateral neck dissection was completed when clinically indicated. Lymphadenectomy of the parotid nodal basin entailed a superficial parotidectomy. The median follow-up for the positive SLN group was 25 months (range, months). The remaining 66 (82.5%) of patients with a negative SLNB result were followed up clinically. Median follow-up for the negative SLN group was 25 months (range, months). During this follow-up interval, 8 (12%) of 66 patients developed recurrent disease. The distribution of recurrences is summarized in Table 3. Three patients had a recurrence of isolated regional disease in a previously mapped nodal basin. Thus, the regional failure rate in the setting of a negative SLNB result, also referred to as the false-negative rate, was 4.5% at a median follow-up interval of 25 months. COMMENT Breslow Depth, mm There are 4 reasons that necessitate the use of SLNB for accurate regional staging of cutaneous melanoma. 10 First, the technique provides important prognostic information to the physician and patient in guiding subsequent treatment options. Second, it helps to identify patients harboring nodal metastases, who then may benefit from Table 3. Location of First Recurrence for 8 Patients in Negative Sentinel Lymph Node Group Primary Tumor Site (Breslow Depth, mm) Lateral neck (5.0) Auricle (1.12) Scalp (3.12) Auricle (1.3) Scalp (2.09) Scalp (2.46) Scalp (3.7) Cheek (2.1) Area of Recurrence Satellite/in-transit Satellite/subcutaneous Skin and pulmonary metastasis Lung and liver metastasis Lung metastasis *Case contributing to false-negative rate of sentinel lymph node mapping with biopsy. early therapeutic lymphadenectomy. Third, it identifies patients who are candidates for adjuvant treatment including interferon alfa-2 and radiation. Fourth, accurate regional staging enables the identification of a homogeneous population of patients for enrollment into clinical trials. Regional metastasis is recognized as an important prognostic factor. Without accurate pathologic staging, stratification is impossible and results of clinical trials will remain inconsistent and difficult to interpret. Fortunately, SLNB provides a minimally invasive means of regional staging. While SLNB is routinely performed for cutaneous trunk and extremity melanoma, 7 the role of this procedure remains uncertain for head and neck cutaneous melanoma. The main concern surrounds the reliability of the SLN to accurately predict the disease status of the entire nodal basin within this region. The interlacing network of cervical lymphatic vessels is often deemed watershed in nature. The complexity of this lymphatic system was demonstrated by O Brien et al 11 who reported a 34% discordance between the clinical prediction of lymphatic drainage and lymphoscintigraphy findings in 97 cases of head and neck cutaneous melanoma. Our study demonstrated that the complexity of the head and neck lymphatic system does not preclude the use of SLNB for staging of cutaneous melanoma. Sentinel lymph node mapping with biopsy in the head and neck region accurately predicts the status of the nodal basin, with 14 (17.5%) of 80 patients identified with a positive SLNB result and 3 (4.5%) of 66 patients developing regional recurrence following a negative SLNB result. A review of other institutional experiences in the use of SLNB for head and neck cutaneous melanoma is presented in Table 3. Studies were included only if information specific to the head and neck sentinel nodes could be ascertained. The 17.5% rate of SLN positivity and the 4.5% false-negative rate reported in our study compares favorably with the success of SLNB achieved in other anatomic sites. 12,13 Reported regional recurrence rates following a negative SLNB result in the head and neck region were quite variable, ranging from 0% to 25% (Table 4). Follow-up time is likely one reason for this variability. Two thirds of recurrences from cutaneous melanoma are expected to occur within 3 years following diagnosis. 22 The 63
4 Table 4. Previous Reports of SLNB for Head and Neck Cutaneous Melanoma Source No. of Patients Positive SLNB Result, % Regional Failure Rate Following a Negative SLNB Result, % Median Follow-up, mo Treatment Modality O Brien et al, LSG + Dye Wells et al, Dye ± LSG + GP* Alex et al, LSG + GP ± Dye Jansen et al, LSG + GP + Dye Carlson et al, LSG + GP ± Dye Rasgon, LSG + GP + Dye Jacobs et al, LSG + GP Patel et al, LSG + GP ± Dye Chi et al, LSG + GP Abbreviations: Dye, vital blue dye; GP, intraoperative gamma probe; LSG, lymphoscintigraphy; plus sign, with; plus/minus sign, with or without; SLNB, sentinel lymph node mapping with biopsy. *Of the patients, 38% underwent mapping with vital blue dye alone. Of the patients, 52% underwent mapping with all 3 treatment modalities. Mean follow-up reported. Vital blue dye used in a few sporadic cases. Of the patients, 85.7% underwent mapping with all 3 treatment modalities. regional recurrence rate of 0% reported by Wells et al 14 included a follow-up interval of only 11.6 months. The 1.9% failure rate reported by Patel et al 20 included a follow-up interval beginning 1 month following SLNB. Our median follow-up of 25 months (range, months) was moderate in duration. Repeat analysis at the 5- to 10-year follow-up interval is warranted to confirm our initial findings. The experience of the surgeon may also account for variability, and a 30-case learning curve has previously been suggested. 7 Studies with higher regional failures compared with our reported 4.5% often involved smaller cohorts of only 20 to 30 patients (Table 4). At our institution, most SLNBs for head and neck melanoma are performed by the 2 senior surgeons. Although retrospective studies often reveal higher failure rates at the beginning of a surgeon s experience, our study did not show that the learning curve contributed to regional failures. 14,23 Following completion of the recommended number of cases that represents the learning curve, 1 regional failure involved the 19th case for one surgeon, while the remaining 2 failures involved the 43rd and 45th case for the second surgeon. This observation reflects the technical challenges involved in performing SLNB. O Brien et al 11 reported that 33% of patients with head and neck cutaneous melanoma who underwent preoperative lymphoscintigraphy had drainage to lymph nodes within the parotid bed. Our distribution was similar, with 30 (26%) of 80 patients mapping to this region. We successfully staged 28 (93.3%) of these 30 patients using SLNB. Although potential injury to the facial nerve from SLNB has led some authors to advocate superficial parotidectomy over the mapping procedure, 8 we successfully removed 39 nodes from 28 parotid basins without facial nerve injury. Similar results were achieved by both senior surgeons, regardless of the use of continuous facial nerve monitoring. Concern has also been expressed that SLNB causes inflammation and fibrosis, which could place the facial nerve at increased risk when reoperation is required to definitively treat the parotid basin in the setting of a positive SLN. 8 In our study, patients with a positive parotid SLN underwent a superficial parotidectomy as a subsequent procedure, and normal facial nerve function was achieved postoperatively in all cases. Our findings are consistent with other reports demonstrating that SLNB can reliably and safely be performed within the parotid nodal basin. 24,25 While the surgeon s experience and technical skill are both vital to the success of SLNB, we attribute our overall low regional failure rate to a team effort involving surgeons, dermatologists, nuclear medicine staff, and pathologists. Appropriate patient selection is imperative because patients with regional or distant metastatic disease or previous surgical disruption of the lymphatic system are not candidates for SLNB. An experienced nuclear medicine staff is necessary because inappropriate administration of the radioactive tracer can lead to shine through, which will render the intraoperative gamma probe useless. Communication with the nuclear medicine team is helpful not only in interpreting the lymphoscintigram, but also to ensure that the appropriate lesion is mapped. Patients with melanoma often present with multiple lesions. It is imperative that only the invasive melanoma is injected with radioactive colloid. One regional failure in this study occurred in a patient who presented for simultaneous treatment of adjacent melanoma and Bowen s disease of the scalp. Subsequent communication with the nuclear medicine team revealed that both lesions were injected, which may have adversely affected the accuracy of SLNB. Lastly, the pathologist plays a critical role in the success of SLNB. Wagner et al 26 reported the mean tumor volume in SLNs positive for metastatic melanoma to be only 4.7 mm 3. Joseph et al 27 reported identification of only 73% of metastatic SLNs using standard H&E staining. Therefore, occult lymphatic metastasis from cutaneous melanoma can be difficult to detect and warrants rigorous pathological analysis including serial sectioning, special immunohistochemical study when indicated, and interpretation by an experienced pathologist. Sentinel lymph node mapping with biopsy provides the pathologist with a limited number of nodes to thoroughly evaluate. There- 64
5 fore, the histologic analysis of SLNs is more thorough and complete compared to the evaluation of the entire lymphadenectomy specimen. 13 CONCLUSIONS Many questions surround the treatment of head and neck cutaneous melanoma. This retrospective study addresses the reliability and safety of SLNB to accurately determine the presence of occult regional spread for head and neck cutaneous melanoma. With a median follow-up of 25 months, 17.5% of patients had a positive SLNB result and only 4.5% of patients developed regional recurrence following a negative SLNB result. The procedure was performed with equivalent safety in both the neck and parotid nodal basins. There were no reported complications of facial nerve weakness or injury to other vital structures. This documented accuracy reported in the setting of minimal morbidity indicates that SLNB is a reliable procedure for regional staging of head and neck cutaneous melanoma. Given that the SLN status is the most important prognostic factor for patients with melanoma, 6 the accuracy of SLNB in the head and neck region demonstrated in the present study is quite promising. Accepted for publication June 27, This study was presented at the annual meeting of the American Head and Neck Society, Boca Raton, Fla, May 11, Corresponding author: Carol R. Bradford, MD, Department of Otolaryngology Head and Neck Surgery, University of Michigan, 1500 E Medical Center Dr, 1904 Taubman Center, Ann Arbor, MI ( cbradfor@umich.edu). REFERENCES 1. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224: Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. Lancet. 1998;351: Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19: Singluff CL, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma. Ann Surg. 1994;219: Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127: Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17: Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. Ann Surg. 1999;230: Eicher SA, Clayman GL, Myers JN, Gillenwater AM. A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2002;128: Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med. 1993; 34: McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol. 2001;19: O Brien CJ, Uren RF, Thompson JF, et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg. 1995;170: Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16: Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000; 7: Wells KE, Rapaport DP, Cruse CW, et al. Sentinel lymph node biopsy in melanoma of the head and neck. Plast Reconstr Surg. 1997;100: Alex JC, Krag DN, Harlow SP, et al. Localization of regional lymph nodes in melanomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124: Jansen L, Koops HS, Nieweg OE, et al. Sentinel node biopsy for melanoma in the head and neck region. Head Neck. 2000;22: Carlson GW, Murray DR, Greenlee R, et al. Management of malignant melanoma of the head and neck using dynamic lymphoscintigraphy and gamma probeguided sentinel lymph node biopsy. Arch Otolaryngol Head Neck Surg. 2000; 126: Rasgon BM. Use of low-dose technetium Tc 99m sulfur colloid to locate sentinel lymph nodes in melanoma of the head and neck: preliminary study. Laryngoscope. 2001;111: Jacobs IA, Chevinsky AH, Swayne LC, Magidson JG, Britto EJ, Smith TJ. Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: reliability of the procedure and analysis of failures after long-term followup. J Surg Oncol. 2001;77: Patel SG, Coit DG, Shaha AR, et al. Sentinel lymph node biopsy for cutaneous head and neck melanomas. Arch Otolaryngol Head Neck Surg. 2002;128: Chi DH, Dorofi DB, Desper E, Levine PA. Lymphoscintigraphy and sentinel node sampling for head and neck melanoma. Presented at: American Academy of Otolaryngology Head and Neck Surgery Foundation Annual Meeting; September 11, 2001; Denver, Colo. 22. Reintgen DS, Vollmer R, Tso CY, Seigler HR. Prognosis for recurrent stage I malignant melanoma. Arch Surg. 1987;122: Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Valdes Olmos RA, Kroon BBR. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. 2000; 87: Wells KE, Stadelmann WK, Rapaport DP, Hamlin R, Cruse CW, Reintgen D. Parotid selective lymphadenectomy in malignant melanoma. Ann Plast Surg. 1999; 43: Ollila DW, Foshag LJ, Essner R, Stern SL, Morton DL. Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma. Ann Surg Oncol. 1999;6: Wagner JD, Davidson D, Coleman JJ, et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol. 1999;6: Joseph E, Brobeil A, Glass F, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol. 1998;5:
Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationORIGINAL ARTICLE. (SLN) biopsy is revolutionizing
ORIGINAL ARTICLE Management of Malignant Melanoma of the Head and Neck Using Dynamic Lymphoscintigraphy and Gamma Probe Guided Sentinel Lymph Node Biopsy Grant W. Carlson, MD; Douglas R. Murray, MD; Robert
More informationLYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY
LYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY Doris Lin, MD, 1 Benjamin L. Franc, MD, 2 Mohammed Kashani-Sabet, MD, 3 Mark
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More informationSentinel lymph node (SLN) biopsy is a wellestablished
ORIGINAL ARTICLE DISCORDANT LYMPHATIC DRAINAGE PATTERNS REVEALED BY SERIAL LYMPHOSCINTIGRAPHY IN CUTANEOUS HEAD AND NECK MALIGNANCIES Alliric I. Willis, MD, John A. Ridge, MD, PhD Department of Surgical
More informationPatent Blue Dye (P.B.D) tums.ac.ir
80-84 1387 2 66 80 : 30 :.. 1385 1382.. Patent Blue Dye (P.B.D). 48 :. - (%47)13 19 195 17.. :.. : * * 88723410 : email: omranipour@ tums.ac.ir. 4 5. Patent Blue Dye (P.B.D) 6-8 %13. %20 1 2. 3 1992 Morton.
More informationTechnical Considerations. Imaging Considerations
354 CUTANEOUS MALIGNANCY OF THE HEAD AND NECK desmoplastic melanomas are characterized by a uniform desmoplasia that is prominent throughout the entire tumor (termed pure desmoplastic melanoma), whereas
More informationWhat Is a Sentinel Node? Re-Evaluating the 10% Rule for Sentinel Lymph Node Biopsy in Melanoma
Journal of Surgical Oncology 2007;95:623 628 What Is a Sentinel Node? Re-Evaluating the 10% Rule for Sentinel Lymph Node Biopsy in Melanoma HIDDE M. KROON, MD, 1 LORI LOWE, MD, 2 SANDRA WONG, MD, 1 DOUG
More informationNodal staging in localized melanoma. The experience of the Brescia Melanoma Unit
The British Association of Plastic Surgeons (2003) 56, 534 539 Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit Giorgio Manca a, *, Fabio Facchetti b, Claudio Pizzocaro
More informationPAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
More informationIncreasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University
More informationORIGINAL ARTICLE. Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax
ORIGINAL ARTICLE Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax Jeffrey D. Wagner, MD; Hee-Myung Park, MD; John J. Coleman III, MD; Charlene Love, RN; John T. Hayes,
More informationPAPER. Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary?
PAPER Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary? Nahel Elias, MD; Kenneth K. Tanabe, MD; Arthur J. Sober, MD; Michele A. Gadd, MD;
More informationSENTINEL LYMPH node (SLN) biopsy has become
COMMENTARY Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement By Kelly M. McMasters, Douglas S. Reintgen, Merrick I. Ross, Jeffrey E. Gershenwald, Michael J. Edwards, Arthur
More informationSentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
More informationSentinel Node Localisation of Melanoma
Sentinel Node Localisation of Melanoma V Bongers, Diakonessenhuis, Utrecht 1. Introduction A melanoma is mostly a malignancy of the skin. The sentinel lymph node (SLN) concept of sequential progression
More informationMelanoma Research 2007, 17: Received 1 April 2007 Accepted 24 August 2007
Original article 365 Sentinel node-guided evaluation of drainage patterns for melanoma of the helix of the ear Thomas Shpitzer a, Haim Gutman b, Yoav Barnea d, Adam Steinmetz c, Dan Guttman a, Dean Ad-El
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationSentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma
Sentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma S. Ross Patton, MD - PGY III Faculty Mentor: Susan McCammon, MD The University of Texas Medical Branch (UTMB Health) Department of Otolaryngology
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More informationSentinel Lymph Node Biopsy Is Accurate and Prognostic in Head and Neck Melanoma
Original Article Sentinel Lymph Node Biopsy Is Accurate and Prognostic in Head and Neck Melanoma Audrey B. Erman, MD 1 *; Ryan M. Collar, MD 1 *; Kent A. Griffith, MPH, MS 2 ; Lori Lowe, MD 3 ; Michael
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationRecurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy
ORIGINAL ARTICLE Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy Melinda V. Davis Malesevich, MD, 1 Ryan Goepfert, MD, 2 Mark Kubik, MD, 1 Dianna B. Roberts,
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationORIGINAL ARTICLE. Sentinel Lymph Node Biopsy for Sebaceous Cell Carcinoma and Melanoma of the Ocular Adnexa
ORIGINAL ARTICLE Sentinel Lymph Node Biopsy for Sebaceous Cell Carcinoma and Melanoma of the Ocular Adnexa Viet H. Ho, MD; Merrick I. Ross, MD; Victor G. Prieto, MD, PhD; Aisha Khaleeq, MD; Stella Kim,
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationUniversity of Groningen
University of Groningen Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome? Doting, E.H.; de Vries, M.; Plukker, John T.H.M.; Jager, P.L.; Post, W.J.; Suurmeijer,
More informationSentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary?
Sentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary? Maurice Y. Nahabedian, MD Anthony P. Tufaro, MD Paul N. Manson, MD The use of sentinel lymph node biopsy for the T1 melanoma is controversial.
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationIs Sentinel Node Biopsy Practical?
Breast Cancer Is Sentinel Node Biopsy Practical? Benefits and Limitations JMAJ 45(10): 444 448, 2002 Shigeru IMOTO *1, Satoshi EBIHARA *2 and Noriyuki MORIYAMA *3 *1 Breast Surgery Division, National Cancer
More informationTotal versus superficial parotidectomy for stage III melanoma
DOI: 10.1002/hed.24810 ORIGINAL ARTICLE Total versus superficial parotidectomy for stage III melanoma Aileen P. Wertz, MD 1 Alison B. Durham, MD 2 Kelly M. Malloy, MD 1 Timothy M. Johnson, MD 2 Carol R.
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationENHANCED SENTINEL LYMPHOSCINTIGRAPHIC MAPPING IN BREAST TUMOR USING THE GRADED SHIELD TECHNIQUE
ENHANCED SENTINEL LYMPHOSCINTIGRAPHIC MAPPING IN BREAST TUMOR USING THE GRADED SHIELD TECHNIQUE Yu-Wen Chen, Yung-Chang Lai, Chien-Chin Hsu, and Ming-Feng Hou 1 Departments of Nuclear Medicine and 1 Gastroenteric
More informationResults, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de
University of Groningen Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de IMPORTANT NOTE: You are advised to consult the publisher's
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationIndex. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035
Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille
More informationAnalysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule
Anatomic Pathology / POISSON PARADIGM AND METASTATIC MELANOMA Analysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule Robin T. Vollmer, MD Key Words:
More informationCanadian Scientific Journal. Intraoperative color detection of lymph nodes metastases in thyroid cancer
Canadian Scientific Journal 2 (2014) Contents lists available at Canadian Scientific Journal Canadian Scientific Journal journal homepage: Intraoperative color detection of lymph nodes metastases in thyroid
More informationClinical Practice Guidelines
Clinical Practice Guidelines Clinical Practice Guidelines for Melanoma Douglas Reintgen, MD, et al H. Lee Moffitt Cancer Center & Research Institute These clinical practice guidelines for melanoma have
More informationKentaro Tanaka, 1 Hiroki Mori, 1 Mutsumi Okazaki, 1 Aya Nishizawa, 2 and Hiroo Yokozeki Introduction. 2. Case Presentation
Case Reports in Oncological Medicine Volume 2013, Article ID 259326, 4 pages http://dx.doi.org/10.1155/2013/259326 Case Report Long-Term Treatment Outcome after Only Popliteal Lymph Node Dissection for
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationReview Article Lymphoscintigraphy Defines New Lymphatic Pathways from Cutaneous Melanoma Site: Clinical Implications and Surgical Management
Radiology Research and Practice Volume 2011, Article ID 817043, 5 pages doi:10.1155/2011/817043 Review Article Lymphoscintigraphy Defines New Lymphatic Pathways from Cutaneous Melanoma Site: Clinical Implications
More informationSPECT/CT Imaging of the Sentinel Lymph Node
IAEA Regional Training Course on Hybrid Imaging SPECT/CT Imaging of the Sentinel Lymph Node Giuliano Mariani Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa, Italy Vilnius,
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationOccurrence of Lymphedema Following Sentinel Node Biopsy (SNB) for Lower Extremity Melanoma
Original Article Elmer Press Occurrence of Lymphedema Following Sentinel Node Biopsy (SNB) for Lower Extremity Melanoma Patrick D. Magoon a, Roger A. Graham b, d, Janice G. Rothschild b, Yoojin Lee c Abstract
More informationDesmoplastic Melanoma: Clinical Behavior and Management Implications
Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic
More informationUniversity of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
More informationAn estimated 68,130 new cases of malignant melanoma
408554OTOXXX10.1177/0194599811408554de Rosa et alotolaryngology Head and Neck Surgery The Author(s) 2010 Reprints and permission: sagepub.com/journalspermissions.nav Systematic Review Sentinel Node Biopsy
More informationAn estimated 76,690 patients will be diagnosed with invasive
SONDAK ET AL Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma Vernon K. Sondak, MD, Sandra L. Wong, MD, Jeffrey E. Gershenwald, MD, and John F. Thompson,
More informationPrognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationAberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men
ORIGINAL ARTICLE Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men Anthony H. Kaveh, BS, 1 Nicole M. Seminara, MD, 1 Melynda
More informationORIGINAL ARTICLE. Regional Lymph Node Metastasis From Cutaneous Squamous Cell Carcinoma
ORIGINAL ARTICLE Regional Lymph Node Metastasis From Cutaneous Squamous Cell Carcinoma Dennis H. Kraus, MD; John F. Carew, MD; Louis B. Harrison, MD Objective: To characterize clinical presentation and
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationLYMPHOSCINTIGRAPHIC DRAINAGE PATTERNS OF THE AURICLE IN HEALTHY SUBJECTS
LYMPHOSCINTIGRAPHIC DRAINAGE PATTERNS OF THE AURICLE IN HEALTHY SUBJECTS Mustafa Asım Aydın, MD, 1 Berna Okudan, MD, 2 Zeynep Dilek Aydın, MD, 3 Feride Meltem Özbek, MD, 2 Serdar Nasır, MD 1 1 Department
More informationSurgery for Melanoma and What s on the Horizon
and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated
More informationCutaneous malignancy is a common disease in
ORIGINAL ARTICLE PATTERNS OF LYMPH NODE SPREAD OF CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Tom J. Vauterin, MD, 1 Michael J. Veness, MMed (Clin Epi), FRANZCR, 2 Garry J. Morgan, FRACDS, FRACS,
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationAdvances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision
Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate
More informationResearch Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre
Skin Cancer Volume 2013, Article ID 904701, 7 pages http://dx.doi.org/10.1155/2013/904701 Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Vera Teixeira, 1
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More informationPAPER. Effect of Multiple Nodal Basin Drainage on Cutaneous Melanoma
PAPER Effect of Multiple Nodal Basin Drainage on Cutaneous Melanoma Andrea C. Federico, BA; Anees B. Chagpar, MD; Merrick I. Ross, MD; Robert C. G. Martin, MD; R. Dirk Noyes, MD; James S. Goydos, MD; Peter
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 9 MARCH 2 27 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Adjuvant Radiation Therapy Is Associated With Improved Survival in Merkel Cell Carcinoma of the Skin Pablo Mojica,
More informationContradiction of Clinical Expectations in Lymphoscintigraphy Sentinel Node Mapping in Detecting Microscopic Melanoma Metastasis
Case Report 474 Contradiction of Clinical Expectations in Lymphoscintigraphy Sentinel Node Mapping in Detecting Microscopic Melanoma Metastasis John WC Chang, MD; Hsui-Fong Chiang, RN; Yung-Feng Lo 1,
More informationPrecision Surgery for Melanoma
Precision Surgery for Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background 87,110 cases of melanoma estimated in
More informationCitation for published version (APA): Huismans, A. (2015). Regional aspects of melanoma diagnosis and treatment [S.l.]: [S.n.]
University of Groningen Regional aspects of melanoma diagnosis and treatment Huismans, Annemarleen IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationEpidemiology. Objectives 8/28/2017
Case based Discussion of Head and Neck Melanoma: Review of Epidemiology, Risk Factors, Identification, Treatments and Prevention Jacqueline M. Doucette MS FNP-C Objectives Define and identify melanoma
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationCitation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.
University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationSentinel Lymph Node Biopsy in Patients With Thin Melanoma
STUDY Sentinel Lymph Node Biopsy in Patients With Thin Melanoma Julie B. Lowe, MD; Eva Hurst, MD; Jeffrey F. Moley, MD; Lynn A. Cornelius, MD Objective: To define the percentage of positive sentinel lymph
More informationUse of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection
456 Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection TOMOKO TAKAMARU 1, GORO KUTOMI 1, FUKINO SATOMI 1, HIROAKI
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationSentinel Node in Malignant Melanoma The Pathologist s Point of View
Sentinel Node in Malignant Melanoma The Pathologist s Point of View S.J. Diaz-Cano Department of Pathology, Barts and The London School of Medicine, University of London, Barts and The London NHS Trust,
More informationFive years of sentinel node biopsy for melanoma: the St George s Melanoma Unit experience
The British Association of Plastic Surgeons (2004) 57, 97 104 Five years of sentinel node biopsy for melanoma: the St George s Melanoma Unit experience Adam Topping a, *, Donald Dewar a, Victoria Rose
More informationNo Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma
No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma Michael Lowe, MD Assistant Professor of Surgery Winship Cancer Institute Emory University School of Medicine July
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationTherapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
More informationThin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis
Ann Surg Oncol DOI 10.1245/s10434-016-5646-9 ORIGINAL ARTICLE MELANOMAS Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis Giorgos
More informationCURRENT ISSUES IN TRANSPLANT DERMATOLOGY
CURRENT ISSUES IN TRANSPLANT DERMATOLOGY NO CONFLICTS OF INTEREST TO DISCLOSE SOLID ORGAN TRANSPLANTATION: 2015 As of April 10, 2015.. 123,319 patients waiting for an organ transplant 2,557 performed this
More informationInguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma
258 research article Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma Nebojsa Glumac 1, Marko Hocevar 1, Vesna Zadnik
More informationMelanoma Extirpation with Immediate Reconstruction: The Oncologic Safety and Cost Savings of Single-Stage Treatment.
RECONSTRUCTIVE Melanoma Extirpation with Immediate Reconstruction: The Oncologic Safety and Cost Savings of Single-Stage Treatment Irena Karanetz, M.D. Sharon Stanley, M.D. Denis Knobel, M.D. Benjamin
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationPAPER. Interval Sentinel Lymph Nodes in Melanoma
PAPER Interval Sentinel Lymph Nodes in Melanoma Kelly M. McMasters, MD, PhD; Celia Chao, MD; Sandra L. Wong, MD; William R. Wrightson, MD; Merrick I. Ross, MD; Douglas S. Reintgen, MD; R. Dirk Noyes, MD;
More information